Diamyd Medical announces preliminary outcome in the company’s rights issue
Summary
Significant results have previously been shown in a large genetically predefined patient group - in a large-scale meta-analysis as well as in the Companys prospective European Phase IIb trial, where Diamyd\xae was administered directly into a superficial lymph node in children and young adults with recently diagnosed Type 1 Diabetes. Investors should not invest in any securities referred to in this press release except on the basis of information contained in the EU Growth Prospectus. The Company has not made an offer to the public to subscribe for or acquire the securities mentioned in this press release in any jurisdiction other than in Sweden. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice.
Funding
Review available funding amount, funding date, investors, and linked company information related to Diamyd Medical announces preliminary outcome in the company’s rights issue in the interactive ISVWorld profile.